Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
FDA Puts Hold on Gilead’s Blood Cancer Therapy Trials cover art

FDA Puts Hold on Gilead’s Blood Cancer Therapy Trials

FDA Puts Hold on Gilead’s Blood Cancer Therapy Trials

Listen for free

View show details
About this listen

The FDA has halted trials for Gilead’s blood cancer therapy due to an increased risk of patient death. This article covers the implications for Gilead Sciences, the drug magrolimab, and the broader landscape of similar treatments in development. Find out more on FinanceVoyager

adbl_web_anon_alc_button_suppression_t1
No reviews yet